San Diego, Oct. 21, 2011 (Shareholders Foundation) -- After PACB shares fell significantly an investigation on behalf of investors in shares of Pacific Biosciences of California (NASDAQ:PACB) over possible Violations of Federal Securities Laws was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Pacific Biosciences of California (NASDAQ:PACB) concerning whether the company, certain of its officers and directors, or others have possibly violated federal securities laws. Specifically, the investigation concerns whether certain statements regarding Pacific Biosciences of Californias business, its prospects and its operations were potentially materially false and misleading at the time they were made.

Pacific Biosciences of California raised approximately $200 million in its initial public offering of stock on October 27, 2010.
However, Pacific Biosciences of Californias Net Loss grew from $21.52million in 2007 to $140.17million in 2010. Despite an increase in its second quarter Revenue from $0.63million last year to $10.63million this year and a slightly decrease in its second quarter Net Loss from $32.71million to $22.48million, Pacific Biosciences of California announced on August 4, 2011 a disclosure of diminished forward earnings potential and that backlog and new orders for its SMRT technology systems were significantly underperforming expectations.
Then on September 20, 2011, Pacific Biosciences of California, Inc. announced that it implemented a reduction in its workforce of approximately 130 employees, or approximately 28% of its total workforce.
Pacific Biosciences of California said it took the action in consideration of uncertainties associated with the economic environment and to position the Company for long-term success.

In under one year shares of Pacific Biosciences of California (Public, NASDAQ: PACB) fell from almost $17 on October 28, 2010 to under $3 per share on October 4, 2011.